Published online Nov 27, 2023. doi: 10.4240/wjgs.v15.i11.2463
Peer-review started: July 27, 2023
First decision: August 10, 2023
Revised: August 18, 2023
Accepted: October 17, 2023
Article in press: October 17, 2023
Published online: November 27, 2023
Processing time: 123 Days and 6.8 Hours
Clinical prognosis often worsens due to high recurrence rates following radical surgery for colon cancer. The examination of high-risk recurrence factors post-surgery provides critical insights for disease evaluation and treatment planning.
To explore the relationship between metastasis-associated factor-1 in colon cancer (MACC1) and vacuolar ATP synthase (V-ATPase) expression in colon cancer tissues, and recurrence rate in patients undergoing radical colon cancer surgery.
We selected 104 patients treated with radical colon cancer surgery at our hospital from January 2018 to June 2021. Immunohistochemical staining was utilized to assess the expression levels of MACC1 and V-ATPase in these patients.
The rates of MACC1 and V-ATPase positivity were 64.42% and 67.31%, respe
The upregulated expression of MACC1 and V-ATPase in colon cancer patients appears to correlate with clinicopathological features and post-radical surgery recurrence.
Core Tip: The abnormal expression of colon cancer metastasis-related factor-1 and vacuolar ATP synthase in colon cancer tissues is related to the clinicopathological characteristics of patients, and is related to the recurrence of colon cancer after radical resection.
- Citation: He M, Cao ZF, Huang L, Zhong WJ, Xu XM, Zeng XL, Wang J. Correlation between the expressions of metastasis-associated factor-1 in colon cancer and vacuolar ATP synthase. World J Gastrointest Surg 2023; 15(11): 2463-2469
- URL: https://www.wjgnet.com/1948-9366/full/v15/i11/2463.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v15.i11.2463
Clinical prognosis often worsens due to high recurrence rates following radical surgery for colon cancer[1,2]. The examination of high-risk recurrence factors post-surgery provides critical insights for disease evaluation and treatment planning[3]. Metastasis-associated factor-1 in colon cancer (MACC1), a metastasis regulation-related factor, fosters epithelial cell invasiveness by increasing stromal infiltration depth, potentially causing metastasis and malignant tumor recurrence[4]. Similarly, the enzyme-binding ATP protease regulator, vacuolar ATP synthase (V-ATPase), regulates ATPase. This action enhances ATPase's binding activity to the tumor cell membrane, thereby optimizing tumor cell energy metabolism and exacerbating abnormal proliferation and division[5]. This study, involved 104 colon cancer patients treated at our hospital, and aimed to comprehensively explore risk factors for recurrence following radical colon cancer surgery. This study focused on the expression of MACC1 and V-ATPase and analyzed the relationship between their expression and the recurrence rate of colon cancer.
A total of 104 patients with colon cancer treated in our hospital from January 2015 to February 2017 were selected, including 56 males and 48 females. Their age ranged from 40 to 71 years old, with a median age of 54.50 years old.
The inclusion criteria were as follows: (1) Patients confirmed to have colon cancer through pathology from tissue samples; (2) Patients who underwent radical colon cancer surgery at our hospital; and (3) Patients who completed clinical follow-up treatment
The exclusion criteria included: (1) Patients receiving preoperative antitumor treatments such as radiotherapy; (2) Patients with other malignant tumors; and (3) Patients with other severe conditions such as autoimmune and metabolic diseases.
The staging of colon cancer refers to the standards in the TNM staging system for colorectal cancer (7th edition) by the American Joint Committee on Cancer/Union for International Cancer Control. Stage I is T1-2N0M0, Stage II is T3-4bN0M0, Stage III is T1-4bN1-2bM0, and Stage IV is T(any)N(any)M1a-1b[6,7].
Paraffin sections were prepared, dehydrated, and subsequently incubated with 3% H2O2 for 20 min at room temperature. The goat serum was washed with phosphate buffer for 3 times, 5 min each time, and the goat serum diluted with phosphate buffer was blocked for 5 min. After pouring off the serum without washing, 5 mL of primary antibody (sourced from Thermo Fisher China, concentration:1:1000) was added. The mixture was incubated at 37 ℃ for 2 h or refrigerated at 4 ℃ for overnight incubation. It was then washed three times with phosphate buffer, each wash lasting 5 min. Next, 3 mL of biotin fluorescence-labeled secondary antibody (sourced from Thermo Fisher China, concentration:1:2000) was added, followed by a 20-30 min incubation at 37 ℃. After three 5-min phosphate buffer washes, Streptavidin/HRP horseradish-labeled streptavidin was added. After incubation at 37 ℃ for another 20-30 min and three more phosphate buffer washes of 5 min each, the enhanced HRP-DAB substrate chromogenic kit (PA110) was used for development. This was followed by rinsing with tap water, restraining, and sealing[8].
This study adopted SPSS 22.0 software to conduct statistical analysis, used χ2 test to compare the counting data, and applied logistic regression analysis to implement multivariate analysis. Inspection level a = 0.05.
The positive expression rates of MACC1 and V-ATPase in colon cancer tissues were significantly higher than those in paracancerous tissues (P < 0.05). See Table 1 for more details.
Group | Cases | MACC1 positive expression (%) | V-ATPase positive expression (%) |
Colon cancer | 104 | 67 (64.42) | 70 (67.31) |
Paracancerous tissue | 104 | 20 (19.23) | 8 (7.69) |
χ2 | 43.647 | 78.851 | |
P value | 0.000 | 0.000 |
The positive expression rates of MACC1 and V-ATPase in patients with TNM stage III, medium and low differentiation, and lymph node metastasis were significantly higher than those in patients with stage I-II, high differentiation and no lymph node metastasis (P < 0.05); MACC1 positive expression rates of patients with tumor diameter > 5 cm were significantly higher than those of patients with tumor diameter ≤ 5 cm (P < 0.05). See Table 2 for more details.
Clinicopathologcal features | Cases | MACC1 positive expression (%) | χ2 | P value | V-ATPase positive expression (%) | χ2 | P value |
Age (years) | |||||||
≤ 55 years old | 54 | 33 (61.11) | 0.538 | 0.463 | 35 (64.81) | 0.317 | 0.573 |
> 55 years old | 50 | 34 (68.00) | 35 (70.00) | ||||
Gender | |||||||
Male | 56 | 35 (62.50) | 0.196 | 0.658 | 40 (71.43) | 0.936 | 0.333 |
Female | 48 | 32 (66.67) | 30 (62.50) | ||||
Tumor site | |||||||
Left colon | 50 | 32 (64.00) | 0.008 | 0.931 | 36 (72.00) | 0.964 | 0.326 |
Right colon | 54 | 35 (64.81) | 34 (62.96) | ||||
TNM staging | |||||||
Phase Ⅰ-Ⅱ | 65 | 34 (52.31) | 11.101 | 0.001 | 35 (53.85) | 14.275 | 0.000 |
Phase Ⅲ | 39 | 33 (84.62) | 35 (89.74) | ||||
Degree of differentiation | |||||||
High differentiation | 31 | 12 (38.71) | 12.74 | 0.000 | 11 (35.48) | 20.327 | 0.000 |
Medium and low differentiation | 73 | 55 (75.34) | 59 (80.82) | ||||
Lymph node metastasis | |||||||
Yes | 49 | 40 (81.63) | 11.973 | 0.001 | 42 (85.71) | 14.266 | 0.000 |
No | 55 | 27 (49.09) | 28 (50.91) | ||||
Vascular infiltration | |||||||
Yes | 41 | 24 (58.54) | 1.023 | 0.312 | 26 (63.41) | 0.466 | 0.496 |
No | 63 | 43 (68.25) | 44 (69.84) | ||||
Nervous system infiltration | |||||||
Yes | 32 | 22 (68.75) | 0.378 | 0.539 | 21 (65.63) | 0.059 | 0.807 |
No | 72 | 45 (62.50) | 49 (68.06) | ||||
Tumor diameter | |||||||
> 5 cm | 60 | 46 (76.67) | 9.276 | 0.002 | 40 (66.67) | 0.026 | 0.871 |
≤ 5 cm | 44 | 21 (47.73) | 30 (68.18) |
The expressions of MACC1 and V-ATPase in colon cancer tissues were positively correlated (rs = 0.797, P < 0.05). See Table 3 for more details.
MACC1 expression | V-ATPase expression | rs | P value | |
Positive | Negative | |||
Positive | 63 | 4 | 0.797 | 0.000 |
Negative | 7 | 30 |
As of September 2019, a total of 72 patients had recurrence, and 32 patients had no recurrence; the positive expression rates of MACC1 and V-ATPase in colon cancer tissues of patients with recurrence were significantly higher than those of patients without recurrence (P < 0.05), as shown in Table 4.
Group | Cases | MACC1 positive expression (%) | V-ATPase positive expression (%) |
Recurrence | 72 | 52 (72.22) | 57 (79.17) |
No recurrence | 32 | 15 (46.88) | 13 (40.63) |
The study used clinicopathological features of the patients and the expressions of MACC1 and V-ATPase as independent variables, and used the recurrence as the dependent variable for Logistic regression analysis. The analysis results showed that TNM staging, lymph node metastasis, MACC1 expression and V-ATPase expression were risk factors for postoperative recurrence (OR = 6.322, 3.435, 2.683 and 2.421, P < 0.05). See Table 5 for more details.
Factor | β | SE | Walds | P value | OR (95%CI) |
TNM staging | 1.844 | 0.411 | 20.130 | 0.000 | 6.322 (2.825-14.148) |
Lymph node metastasis | 1.234 | 0.315 | 15.346 | 0.000 | 3.435 (1.853-6.369) |
MACC1 expression | 0.987 | 0.264 | 13.977 | 0.000 | 2.683 (1.599-4.502) |
V-ATPase expression | 0.884 | 0.221 | 16.000 | 0.000 | 2.421 (1.570-3.733) |
The recurrence of colon cancer post-radical surgery is intricately linked to factors such as the excised tumor lesion's completeness, the biological activity of tumor cells, and the self-proliferation traits of residual tumor cells[9,10]. For patients with poorly differentiated tumor cells or in advanced clinical stages, the risk of recurrence may progressively rise post-surgery, correspondingly increasing the mortality rate[11,12]. Currently, reliable indicators to assess the risk of post-surgical recurrence in colon cancer are scarce. While postoperative clinicopathological staging or immunohistochemical indicators can offer some degree of predictability, their reliability remains insufficient. Imaging techniques can aid in predicting recurrence; however, most patients are usually in the intermediate to advanced disease stages when recurrence is clinically diagnosed, limiting the assessment's early recurrence value[13,14].
Our study analyzed MACC1 and V-ATPase-two factors integral to tumor cell gene regulation and energy metabolism-providing a dependable recurrence risk prediction model for clinical use. We chose to examine MACC1 and V-ATPase expression due to their influence on the, regulation of colon cancer cell proliferation.
MACC1, a metastasis regulation-related factor, contains serine and sulfhydryl protein structures. These can impact the activity of tumor cell membrane-bound proteins via phosphorylation. MACC1's activation on G protein-coupled receptors in tumor cells can heighten the abnormal transcriptional activation of nuclear DNA in colon cancer cells. As an ATPase protein-binding factor, MACC1's; effect on adenosine triphosphate can boost ATP synthesis in tumor cells, the synthetic division of tumor cell spindles, and tumor cell proliferation[15]. Certain researchers have analyzed MACC1 expression in patients with colon cancer proposing that an elevated MACC1 positive expression rate may increase the risk of colon cancer[16,17]. On the other hand, studies on V-ATPase are sparse, with, most resorting to univariate analysis. To better understand these variables' relationships, we conducted a correlation study.
We discovered that the positive expression rates of MACC1 and V-ATPase proteins in colon cancer lesions significantly exceeded those in paracancerous tissues. This suggests that higher expression of these two proteins might impact the onset or progression of colon cancer. Such high expression is primarily driven by the activation of the transcriptional regulatory signaling pathway in colon cancer cells. This influences the synthesis rates of adenosine triphosphate and guanosine triphosphate, enhances ATP supply, and ultimately impacts the tumor cells' metastasis and adhesion capabilities.
In patients with TNM stage III, medium and low differentiation, and lymph node metastasis, MACC1 and V-ATPase expression rates were significantly higher compared to patients with stage I-II, high differentiation, and no lymph node metastasis. This indicates that the expression of these two factors can markedly influence the prognosis of clinicopathological processes in patients with colon cancer. High expression of MACC1 primarily impacts clinical staging, lymph node metastasis, or tumor cell differentiation because it can affect the epithelial-mesenchymal transition process, intensify tumor cell infiltration and metastasis, and ultimately advance TNM staging. V-ATPase's influence on related pathological characteristics chiefly stems from its capacity to affect tumor cells' energy metabolism rate, leading to the compromised release of tumor cell differentiation and maturation-inducing factors, thereby promoting medium and low differentiation of tumor cells[18].
Further studies have also demonstrated that in colon cancer patients, the MACC1 expression level significantly rises with clinical staging progression. This increase is notably pronounced for patients in the advanced or terminal stages of colon cancer[19,20]. Our correlation analysis revealed a positive correlation between MACC1 and V-ATPase expression in colon cancer tissues, suggesting a collaborative role of MACC1 and V-ATPase in colon cancer progression. In patients who experienced recurrence, the positive expression rates of MACC1 and V-ATPase proteins markedly increased and surpassed those in non-recurrence patients. This statistically significant difference implies that high MACC1 and V-ATPase protein expression can influence colon cancer recurrence. However, the specific underlying mechanism remains unclear, but it could involve MACC1 and V-ATPase impacting the activity of residual tumor cells, leading to an enhanced self-proliferation capacity and ultimately promoting colon cancer recurrence. Risk factor analysis further identified TNM stage, lymph node metastasis, MACC1 expression, and V-ATPase expression as risk factors for postoperative recurrence, underscoring the influence of MACC1 and V-ATPase on colon cancer recurrence.
Colon cancer's development is governed by numerous cytokines. Clinical studies have largely focused on single-factor regulation, the functionality of which can be swayed by various environmental relationships. A multifactor correlation analysis could offer greater value for clinical diagnosis. In this study, we jointly examined MACC1 and V-ATPase's clinical value in this disease, using the patients' clinicopathological characteristics and MACC1 and V-ATPase expression as independent variables, and recurrence as the dependent variable for logistic regression analysis. The results suggested these two indicators might pose as risk factors for postoperative recurrence in colon cancer patients. High MACC1 expression could foster the metastasis of various tumor cells, although the specific mechanism of action remains unelucidated. MACC1 protein could not only augment tumor metastasis by regulating Met transcription but also modulate cell metastasis by activating the Akt/β-catenin signaling pathway or promoting the secretion of matrix metalloproteinases. Overexpression of V-ATPase in tumor cells plays a crucial role in maintaining the cytoplasm's alkaline environment, stimulating tumor cell growth, enhancing the extracellular acidic environment, promoting cell invasive growth and metastasis, and inducing the invasive phenotype of tumor cells. Thus, our study can serve as a reference for clinical prediction of the postoperative recurrence in colon cancer patients. However, there were some limitations of this study. The patients were selected from one single center, and the sample size was limited. The results of this study need to be confirmed by further studies.
In summary, the elevated expression of MACC1 and V-ATPase in colon cancer patients is associated with the clinicopathological features and post-radical surgery recurrence of colon cancer, and warrants further investigation.
Clinical prognosis often worsens due to high recurrence rates following radical surgery for colon cancer. The examination of high-risk recurrence factors post-surgery provides critical insights for disease evaluation and treatment planning.
The factors influencing the recurrence of colon cancer after surgery remains unclear.
To explore the relationship between metastasis-associated factor-1 in colon cancer (MACC1) and vacuolar ATP synthase (V-ATPase) expression in colon cancer tissues, and recurrence rate in patients undergoing radical colon cancer surgery.
We selected 104 patients treated with radical colon cancer surgery at our hospital from January 2018 to June 2021. Immunohistochemical staining was utilized to assess the expression levels of MACC1 and V-ATPase in these patients.
The positive rates of MACC1 and V-ATPase were significantly higher in patients with recurrence compared to those without. Logistic regression analysis revealed TNM stage, lymph node metastasis, MACC1 expression, and V-ATPase expression as risk factors for postoperative colon cancer recurrence.
The upregulated expression of MACC1 and V-ATPase in colon cancer patients appears to correlate with clinicopathological features and post-radical surgery recurrence.
This study can serve as a reference for clinical prediction of the postoperative recurrence in colon cancer patients.
Provenance and peer review: Unsolicited article; Externally peer reviewed.
Peer-review model: Single blind
Specialty type: Gastroenterology and hepatology
Country/Territory of origin: China
Peer-review report’s scientific quality classification
Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0
P-Reviewer: Derkus B, Turkey; Tortora G, Italy S-Editor: Fan JR L-Editor: A P-Editor: Fan JR
1. | Emile SH. Radical resection of colon cancer: More isn't necessarily better. Surgery. 2022;171:555. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
2. | Zheng YY, Wang X, Si JT, Sun YX, Hou WB, Liu JP, Li YX, Liu ZL. Randomized clinical trials of traditional chinese medicines for treating ulcerative colitis: A scoping review. World J Tradit Chin Med. 2021;7:326-331. [DOI] [Cited in This Article: ] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
3. | Gu J, Deng S, Cao Y, Mao F, Li H, Wang J, Wu K, Cai K. Application of endoscopic technique in completely occluded anastomosis with anastomotic separation after radical resection of colon cancer: a case report and literature review. BMC Surg. 2021;21:201. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
4. | Shen J, Zang S, Yu X, Zhao F, Jiang P, Zhong B, Zhou H, Yan S. Management of biochemical recurrence after radical prostatectomy for prostate cancer: A case report. Medicine (Baltimore). 2019;98:e16351. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
5. | Li Z, Zou Z, Lang Z, Sun Y, Zhang X, Dai M, Mao S, Han Z. Laparoscopic versus open radical resection for transverse colon cancer: evidence from multi-center databases. Surg Endosc. 2021;35:1435-1441. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
6. | Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, Bilchik AJ. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? J Am Coll Surg. 2013;217:181-190. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 165] [Cited by in F6Publishing: 202] [Article Influence: 18.4] [Reference Citation Analysis (0)] |
7. | Mao X, Wang J, Luo F. Alpha-fetoprotein can promote gastric cancer progression via upregulation of metastasis-associated colon cancer 1. Oncol Lett. 2022;23:84. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (0)] |
8. | Zafar SN, Hu CY, Snyder RA, Cuddy A, You YN, Lowenstein LM, Volk RJ, Chang GJ. Predicting Risk of Recurrence After Colorectal Cancer Surgery in the United States: An Analysis of a Special Commission on Cancer National Study. Ann Surg Oncol. 2020;27:2740-2749. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis (0)] |
9. | Zhang X, Luo Y, Cen Y, Qiu X, Li J, Jie M, Yang S, Qin S. MACC1 promotes pancreatic cancer metastasis by interacting with the EMT regulator SNAI1. Cell Death Dis. 2022;13:923. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 10] [Reference Citation Analysis (0)] |
10. | Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:329-359. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 234] [Cited by in F6Publishing: 730] [Article Influence: 243.3] [Reference Citation Analysis (0)] |
11. | Jin JQ, Jia XN, Xuan JY. [Changes of intestinal flora and miR-10a expression after radical operation of colorectal cancer: Effect of microecological enteral nutrition intervention]. Shijie Huaren Xiaohua Zazhi. 2021;29:356-365. [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
12. | Fabregas JC, Ramnaraign B, George TJ. Clinical Updates for Colon Cancer Care in 2022. Clin Colorectal Cancer. 2022;21:198-203. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 1] [Reference Citation Analysis (1)] |
13. | Chattopadhyay I, Dhar R, Pethusamy K, Seethy A, Srivastava T, Sah R, Sharma J, Karmakar S. Exploring the Role of Gut Microbiome in Colon Cancer. Appl Biochem Biotechnol. 2021;193:1780-1799. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 23] [Cited by in F6Publishing: 54] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
14. | Cui Y, Yu S, Zhu M, Cheng X, Yu Y, Tang Z, Wang X, Hou J, Hou Y, Ren D, Mao B, Khalid R, Liu T. Identifying Predictive Factors of Recurrence after Radical Resection in Gastric Cancer by RNA Immune-oncology Panel. J Cancer. 2020;11:638-647. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
15. | Pan L, Sun GP. [Risk stratification analysis of recurrence after radical operation of colorectal cancer]. Shijie Huaren Xiaohua Zazhi. 2018;26:1186-1192. [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
16. | Qian X, Zhao Y, Zhang T, Fan P. Downregulation of MACC1 facilitates the reversal effect of verapamil on the chemoresistance to active metabolite of irinotecan in human colon cancer cells. Heliyon. 2022;8:e11294. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
17. | Bähr I, Jaeschke L, Nimptsch K, Janke J, Herrmann P, Kobelt D, Kielstein H, Pischon T, Stein U. Obesity, colorectal cancer and MACC1 expression: A possible novel molecular association. Int J Oncol. 2022;60. [PubMed] [DOI] [Cited in This Article: ] [Reference Citation Analysis (0)] |
18. | Li A, Käsmann L, Rades D, Fu C. A Scoring System to Predict the Development of Bone Metastasis After Radical Resection of Colorectal Cancer. Anticancer Res. 2017;37:5169-5172. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
19. | Esmail S, Kartner N, Yao Y, Kim JW, Reithmeier RAF, Manolson MF. N-linked glycosylation of a subunit isoforms is critical for vertebrate vacuolar H(+) -ATPase (V-ATPase) biosynthesis. J Cell Biochem. 2018;119:861-875. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
20. | Güllü N, Smith J, Herrmann P, Stein U. MACC1-Dependent Antitumor Effect of Curcumin in Colorectal Cancer. Nutrients. 2022;14. [PubMed] [DOI] [Cited in This Article: ] [Cited by in F6Publishing: 6] [Reference Citation Analysis (0)] |